Gene Panel Market Size

Gene Panel Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The gene panel market is expected to grow significantly from a current market size of $ 1.62 billion in 2025 to $ 5.14 billion in 2034, at a robust CAGR of 13.72%. This upward trend is due to the growing demand for genetic tests and personalized medicine, driven by the advancement in gene-based technology and the rising prevalence of genetic disorders. As the health system in many countries is gradually shifting towards precision medicine, gene panels are becoming more common, enabling physicians to make an informed decision based on genetic information. Gene panels are also expected to grow significantly due to the increasing incidence of hereditary diseases, the decreasing cost of gene-based technology, and the growing focus on preventive medicine. The advancement in next-generation sequencing and bioinformatics has made gene panels more accurate and efficient, making them more accessible to health care professionals. The major players in the market, such as Illumina, Thermo Fisher Scientific, and Agilent Technologies, are constantly expanding their business through strategic collaborations and product launches. For example, the recent integration of artificial intelligence into the analysis of genomic data is expected to further accelerate the adoption of gene panels in clinical settings.

Regional Market Size

Regional Deep Dive

GENE PANEL MARKET is growing at a significant rate across all regions, owing to advancements in genomic technology, rising prevalence of genetic disorders and increasing demand for individualized medicine. In North America, the market is characterized by strong health care system, high investment in R&D, and presence of key players. Europe is characterized by a diverse regulatory environment and a growing focus on precision medicine. The Asia-Pacific region is characterized by rising healthcare expenditure and technological advancements. The Middle East and Africa region is gradually emerging as a potential market, owing to increasing investment in healthcare and genetic research. Latin America is also beginning to invest in the field of genetic testing, driven by rising awareness and government initiatives.

North America

• Recent approvals by the FDA of several gene-based tests have enhanced the regulatory framework and stimulated innovation in the marketplace.
• Illumina and Thermo Fisher are investing heavily in R&D to develop the next-generation sequencing, which is expected to drive market growth.
• The growing occurrence of hereditary diseases and the demand for individualized medicine are driving the demand for comprehensive gene panels.

Europe

• Among the projects supported by the Horizon 2020 programme are many aimed at advancing the study of genetics and the development of gene panels.
• The market for genetic diagnostics is undergoing change. The new European regulations on in vitro diagnostics are bringing the quality of these products up to a higher level.
• The gene panel is being adopted in many countries, with Germany and the UK at the forefront. There are national health programmes which encourage genetic testing for the early detection of disease.

Asia-Pacific

• China's National Health Commission has made genetic testing a routine test for routine health examinations, which has greatly promoted the gene panel market.
• In India, biotech companies such as MedGenome have sprung up to help with the development and availability of genetic testing.
• Across the Asia-Pacific region, the rising investments in the health care sector and the growing awareness of genetic disorders are accelerating the adoption of gene panels.

MEA

• The United Arab Emirates has embarked on a number of government programmes to develop its genetic research and testing capabilities and establish itself as a regional centre for genetics.
• Universities and international biotech companies are collaborating to develop new gene panels in the region.
• Culture and the growing emphasis on preventive medicine also influence the acceptance and demand for genetic testing services.

Latin America

• The public health authorities in Brazil are supporting genetic screening programs, which are aimed at improving health care and preventing disease.
• There are now local companies that are collaborating with foreign companies to increase the availability of gene panels, which are a reflection of the growing interest in personal medicine.
• The growing number of hereditary diseases in the region is forcing physicians to adopt gene panels as a standard diagnostic tool.

Did You Know?

“By way of example, some 80% of rare diseases are thought to have a genetic basis, indicating the critical importance of genetic panels in diagnosis and treatment.” — National Institutes of Health (NIH)

Segmental Market Size

The Gene-Panel Market is a fast-growing segment in the broader genomics market, owing to the increasing demand for personal medicine and the technological advances in genetic testing. The Gene-Panel Market is characterized by the ability to provide a targeted view of the genetic predisposition, which in turn increases the prevention and treatment of diseases. The market is currently growing strongly due to the rising awareness of consumers and the integration of genetic testing into everyday medical practices.

The main demand drivers are the increasing frequency of genetic diseases and the trend towards individualized medicine, which requires extensive genetic testing. Furthermore, regulatory support for next-generation sequencing, such as that of the FDA, also supports the market. This market is currently in a mature stage of development. The market is dominated by companies such as Illumina and Thermo Fisher Scientific. The main application areas are oncology, where gene panels are used for the screening of tumors, and hereditary diseases, as is exemplified by initiatives in North America and Europe. The pandemic COV19 is expected to accelerate the uptake of genetic testing, while CRISPR and bioinformatics will have a decisive influence on the future of gene panels.

Future Outlook

The Gene Panels Market is expected to grow at a significant CAGR of 13.72% from 2025 to 2035. This growth is attributed to the rising prevalence of genetic disorders, advancements in genomic technology, and the rising importance of personalized medicine. Gene panels, which help in early diagnosis and targeted treatment, are in high demand. Gene panel testing is expected to account for nearly a quarter of the total global diagnostics market by 2035, up from an estimated 10% in 2025, indicating a major shift in the clinical practice towards genetic testing.

A number of technological developments, such as the use of next-generation sequencers and bioinformatics, will enhance the accuracy and efficiency of gene panel tests, thus making them more accessible and cost-effective. In addition, the favourable policies and funding initiatives of governments and health organisations will promote genetic research and testing. Meanwhile, the emergence of direct-to-consumer genetic testing and the integration of artificial intelligence into the analysis of genomic data will change the landscape of the gene panel market. These trends will require the industry to adopt a flexible approach if it is to seize the opportunities presented by this rapidly evolving and growing market.